Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs

European Journal of Clinical Pharmacology

Volumn 73, Issue 10, 2017, Pages 1315-1322

  Komen, Joris ^a,b   Forslund, Tomas ^a,c   Hjemdahl, Paul ^a   Wettermark, Björn ^a,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UTRECHT UNIVERSITY   (Netherlands)

^c STOCKHOLM COUNTY COUNCIL   (Sweden)

Author keywords

Antithrombotic treatment; Atrial fibrillation; NOACs; Stockholm

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CLOPIDOGREL; DABIGATRAN; RIVAROXABAN; WARFARIN; FIBRINOLYTIC AGENT;

ADOLESCENT; ADULT; AGED; ALCOHOLISM; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DECISION MAKING; DEMENTIA; DIABETES MELLITUS; FALLING; FEMALE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFANT; KIDNEY DISEASE; LIVER DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; NEWBORN; OBESITY; PATIENT SELECTION; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VENOUS THROMBOEMBOLISM; VERY ELDERLY; BLOOD; CHEMICALLY INDUCED; CLINICAL DECISION MAKING; MULTIVARIATE ANALYSIS; RISK FACTOR;

AGED; ATRIAL FIBRILLATION; CLINICAL DECISION-MAKING; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 85021697794     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-017-2289-0     Document Type: Article

References (30)

1. [No authors listed] (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 154:1449
2. Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857–867
3. Friberg L, Bergfeldt L (2013) Atrial fibrillation prevalence revisited. J Intern Med 274:461–468
4. European Medicines Agency (2009) Pradaxa: EPAR - Product Information http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf. Accessed 29 Feb 2016
5. European Medicines Agency (2009) Xarelto: EPAR - Product Information http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Accessed 29 Feb 2016
6. European Medicines Agency (2011) Eliquis: EPAR - Product Information http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf. Accessed 29 Feb 2016
7. Komen J, Forslund T, Hjemdahl P, Andersen M, Wettermark B (2016) Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. Br J Clin Pharmacol. doi:10.1111/bcp.13150
8. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151
9. Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891
10. Granger CB, Alexander JH, McMurray JJV et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992
11. Eichler H-G, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, Rowland M, Schneider CK, Bloechl-Daum B (2011) Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov 10:495–506
12. Desai NR, Krumme AA, Schneeweiss S et al (2014) Patterns of initiation of oral anticoagulants in patients with atrial fibrillation—quality and cost implications. Am J Med 127:1075–1082 e1
13. Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH, Murray E (2007) Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet (London) 370:493–503
14. Connolly SJ, Eikelboom J, Joyner C et al (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806–817
15. Stockholm County Council (Healthcare Region) (2015) The Wise List 2015
16. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. Europace 14:1385–1413
17. Forslund T, Wettermark B, Wändell P, von Euler M, Hasselström J, Hjemdahl P (2014) Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. Eur J Clin Pharmacol 70:1477–1485
18. Ha ACT, Singh N, Cox JL et al (2016) Oral anticoagulation for stroke prevention in Canadian practice: Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF) Registry(.) Can J Cardiol 32:204–210
19. Steinberg BA, Holmes DN, Piccini JP et al (2013) Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc 2:e000535
20. Schoof N, Schnee J, Schneider G, Gawlik M, Zint K, Clemens A, Bartels DB (2014) Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US. Curr Med Res Opin 30:795–804
21. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G (2015) Factors driving anticoagulant selection in patients with atrial fibrillation in the United States. Am J Cardiol 115:1095–1101
22. Forslund T, Wettermark B, Wändell P, von Euler M, Hasselström J, Hjemdahl P (2013) Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system. Int J Cardiol 170:208–214
23. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A (2009) The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 24:659–667
24. Wettermark B, Hammar N, Fored CM et al (2007) The new Swedish prescribed drug register--opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16:726–735
25. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272
26. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE (2011) A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 58:395–401
27. Bauer KA (2013) Pros and cons of new oral anticoagulants. Hematol Am Soc Hematol Educ Program 2013:464–470
28. Mason A (2008) New medicines in primary care: a review of influences on general practitioner prescribing. J Clin Pharm Ther 33:1–10
29. Olesen JB, Sørensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP, Køber L, Gislason GH, Torp-Pedersen C, Fosbøl EL (2015) Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace 17:187–193
30. Gasparini A, Evans M, Coresh J et al (2016) Prevalence and recognition of chronic kidney disease in Stockholm healthcare. Nephrol Dial Transplant. doi:10.1093/ndt/gfw354